| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.7 |